As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.
10 Analysts have issued a Heron Therapeutics Inc forecast:
10 Analysts have issued a Heron Therapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 155 155 |
13%
13%
|
|
| Gross Profit | 115 115 |
15%
15%
|
|
| EBITDA | 3.96 3.96 |
117%
117%
|
|
| EBIT (Operating Income) EBIT | 1.60 1.60 |
106%
106%
|
|
| Net Profit | -14 -14 |
51%
51%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.
| Head office | United States |
| CEO | Craig Collard |
| Employees | 122 |
| Founded | 1983 |
| Website | www.herontx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


